Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kunfukang Tablets (坤复康片) is a Traditional Chinese Medicine (TCM) formulation developed and marketed by Shaanxi Kanghui Pharmaceutical. It is primarily indicated for the treatment of gynecological inflammatory conditions, most notably chronic pelvic inflammatory disease (PID). According to TCM theory, the drug is designed to clear heat, resolve dampness, promote blood circulation, and remove blood stasis. The formulation typically consists of several herbal ingredients, including *Sophora flavescens*, *Patrinia villosa*, *Paeonia lactiflora*, and *Curcuma zedoaria*. It is part of the company's established portfolio of Chinese patent medicines and is administered orally to manage symptoms such as pelvic pain and abnormal vaginal discharge associated with inflammatory stasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kunfukang Tablets.